Dr. Kelly E. Caudle discusses considerations behind CPIC guideline development and ongoing work to continually evolve the list of drug-gene interactions recognized by regulatory bodies. Learn about:
- Translating genetic laboratory test results into actionable prescribing decisions
- CPIC’s goal to address the barrier to clinical implementation of pharmacogenetic tests
- Ongoing efforts to provide practice guidelines that align to actionable pharmacogenomic information
Kelly E. Caudle, Pharm.D., Ph.D.
BCPS Principal Investigator and Director,
Clinical Pharmacogenetics Implementation Consortium
Learn more about our pharmacogenetics solutions.